Yusuke Masuo

Dr. Yusuke Masuo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
NHNaoto Hashimoto
Naoto Hashimoto
NNNoritaka Nakamichi
Noritaka Nakamichi
EYErina Yamazaki
Erina Yamazaki
MOMasashi Oikawa
Masashi Oikawa
YMYusuke Masuo
Yusuke Masuo
YKYukio Kato
Yukio Kato
ATP binding cassette transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), are expressed in skin, but their involvement in transdermal absorption of clinically used drugs remains unknown. Here, we examined their role in transdermal absorption of corticosteroids. Skin and plasma concentrations of dexamethasone after dermal application were reduced in P-gp and BCRP triple-knockout (Mdr1a/1b/Bcrp-/-) mice. The skin concentration in Mdr1a/1b/Bcrp-/- mice was reduced in the dermis, but not in the epidermis, indicating that functional expression of these transporters in skin is compartmentalized. Involvement of these transporters in dermal transport of dexamethasone was also supported by the observation of a higher epidermal concentration in Mdr1a/1b/Bcrp-/- than wild-type mice during intravenous infusion. Transdermal absorption after dermal application of prednisolone, but not methylprednisolone or ethinyl estradiol, was also lower in Mdr1a/1b/Bcrp-/- than in wild-type mice. Transport studies in epithelial cell lines transfected with P-gp or BCRP showed that dexamethasone and prednisolone are substrates of P-gp, but are minimally transported by BCRP. Thus, our findings suggest that P-gp is involved in transdermal absorption of at least some corticosteroids in vivo. P-gp might be available as a target for inhibition in order to deliver topically applied drugs and cosmetics in a manner that minimizes systemic exposure.

10 April 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
GPGyujin Park
Gyujin Park
KFKazuya Fukasawa
Kazuya Fukasawa
THTetsuhiro Horie
Tetsuhiro Horie
YMYusuke Masuo
Yusuke Masuo
YIYuka Inaba
Yuka Inaba
EHEIICHI HINOI
EIICHI HINOI
Hypothalamic neurons regulate body homeostasis by sensing and integrating changes in the levels of key hormones and primary nutrients (amino acids, glucose, and lipids). However, the molecular mechanisms that enable hypothalamic neurons to detect primary nutrients remain elusive. Here, we identified l-type amino acid transporter 1 (LAT1) in hypothalamic leptin receptor–expressing (LepR-expressing) neurons as being important for systemic energy and bone homeostasis. We observed LAT1-dependent amino acid uptake in the hypothalamus, which was compromised in a mouse model of obesity and diabetes. Mice lacking LAT1 (encoded by solute carrier transporter 7a5, Slc7a5 ) in LepR-expressing neurons exhibited obesity-related phenotypes and higher bone mass. Slc7a5 deficiency caused sympathetic dysfunction and leptin insensitivity in LepR-expressing neurons before obesity onset. Importantly, restoring Slc7a5 expression selectively in LepR-expressing ventromedial hypothalamus neurons rescued energy and bone homeostasis in mice deficient for Slc7a5 in LepR-expressing cells. Mechanistic target of rapamycin complex-1 (mTORC1) was found to be a crucial mediator of LAT1-dependent regulation of energy and bone homeostasis. These results suggest that the LAT1/mTORC1 axis in LepR-expressing neurons controls energy and bone homeostasis by fine-tuning sympathetic outflow, thus providing in vivo evidence of the implications of amino acid sensing by hypothalamic neurons in body homeostasis.

1 December 2019 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TTTakayuki Taguchi
Takayuki Taguchi
YMYusuke Masuo
Yusuke Masuo
YSYoshiyuki Sakai
Yoshiyuki Sakai
YKYukio Kato
Yukio Kato

8 May 2026
Verified
Book Chapter
Open access
PDF file
TMTetsuya Matsukawa
Tetsuya Matsukawa
SMShigehiko Mizutani
Shigehiko Mizutani
HMHidesuke Mizutani
Hidesuke Mizutani
KMKunio Matsumoto
Kunio Matsumoto
YKYukio Kato
Yukio Kato
HKHiroaki Kajiyama
Hiroaki Kajiyama
The reduced uterine perfusion pressure model in pregnant rats closely mimics the pathophysiology of preeclampsia. Preeclampsia frequently occurs in high-altitude populations. Evidence suggests that fetal hypoxia is involved in the pathogenesis of preeclampsia. We proposed that the crosstalk between fetal angiotensin II (Ang-II) and vasopressin, and their degrading aminopeptidases (APs) in both the placenta and maternal blood, regulates placental circulation. Therefore, changes in maternal blood AP levels may reflect changes in placental circulation. Our present review contributes to the understanding of dynamic changes in placental circulation in preeclampsia and suggests that the pathophysiology of preeclampsia can be interpreted as a disturbance in the redistribution of blood flow to the placenta under fetal hypoxia. Furthermore, changes in APs in maternal blood may help explain two longstanding concepts in preeclampsia research: changes in responses to exogenous Ang-II and placental perfusion in preeclampsia. These findings also highlight the potential of placental APs as a future therapeutic target for preeclampsia.